[病毒性肝炎和怀孕]
Imane Ben M'Barek1, Jeanne Sibiude2, Élise Bouthry3
1Université aris Cité, ervice de ynécologieobstétrique, Beaujon, AP-HP, FETUS URP 7328, Clichy, France.
La Revue du praticien
|January 23, 2026
概括
怀孕期间的病毒性肝炎存在多种风险. 乙型肝炎的管理包括查和抗病毒药物,以防止母婴传播,而其他类型,如乙型肝炎,具有严重的风险.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 产科 产科 产科 产科 产科
- 传染性疾病 传染性疾病
背景情况:
- 病毒性肝炎包括几种不同的病毒 (A,B,C,D,E),传播途径和临床影响各不相同.
- 怀孕可以改变病毒性肝炎的过程,增加母亲和胎儿的风险.
- 了解怀孕期间与每种肝炎类型相关的特定风险对于有效管理至关重要.
研究的目的:
- 审查不同类型的病毒性肝炎对怀孕结果的影响.
- 概述每个肝炎病毒产科并发症和垂直传播的风险.
- 总结当前的管理策略,包括查和治疗,怀孕期间的病毒性肝炎.
主要方法:
- 在怀孕期间对病毒性肝炎的文献综述.
- 分析传染途径,产科并发症和甲型,乙型,乙型,乙型,乙型和乙型肝炎的垂直传播风险.
- 管理指南的摘要,包括产前查和抗病毒疗法.
主要成果:
- 甲型肝炎:通常是轻微的,但可能会增加产科并发症的风险.
- 乙型肝炎:最常见,具有显著的母婴传播风险,通过查和抗病毒药物进行管理.
- 肝炎C:主要是通过血液传播的,对怀孕的影响进行了讨论.
- 肝炎D:超级感染 肝炎B,孕期治疗选择有限.
- 肝炎E:在孕期第三季度严重,存在发性肝炎的风险,罕见的母婴传播.
- 总的来说,母婴传播很少见,母乳养通常是允许的.
结论:
- 怀孕期间病毒性肝炎的临床表现和风险是特定类型的.
- 积极的管理,包括查和向治疗 (尤其是乙型肝炎),对于降低风险至关重要.
- 对于在孕妇群体中治疗D型肝炎可能需要进一步的研究.
相关概念视频
Viral Recombination
25.0K
Cells are sometimes infected by more than one virus at once. When two viruses disassemble to expose their genomes for replication in the same cell, similar regions of their genomes can pair together and exchange sequences in a process called recombination. Alternatively, viruses with segmented genomes can swap segments in a process called reassortment.
25.0K
Viral Structure
74.1K
Viruses are extraordinarily diverse in shape and size, but they all have several structural features in common. All viruses have a core that contains a DNA- or RNA-based genome. The core is surrounded by a protective coat of proteins called the capsid. The capsid is composed of subunits called capsomeres. The capsid and genome-containing core are together known as the nucleocapsid.
74.1K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
261
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
261
Hepatic Portal System
5.6K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
5.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
219
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
219
Viral Mutations
39.8K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
39.8K


